Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Kyoto
Clinical trial register · Japan

Clinical Trials in Kyoto, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Chūōku 90 Fukuoka 84 Kashiwa 72 Bunkyō City 61 Kōtoku 56
Narrow the registerReset
Recruitment status
Phase
Site location
Chūōku90 Fukuoka84 Kashiwa72 Bunkyō City61 Kōtoku56
All 186 locations
Target enrolment
to

Trials with a site in Kyoto

21 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
AstraZeneca
Phase 3
500
Chūōku, Ichinomiya-shi, Izunokuni-shi, Kamakura-shi, Kawagoe-shi, Kitakyushu-shi, Kyoto, Mito
2026-08-24
Recruiting
AstraZeneca
Phase 3
600
Asahikawa-shi, Kamakura-shi, Kashiwa-shi, Kobe, Komoro, Kumamoto, Kyoto, Miyazaki
2026-07-08
Recruiting
AstraZeneca
Phase 3
900
Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi
2026-07-06
Recruiting
AstraZeneca
Phase 3
750
Fukuoka, Kyoto, Nishinomiya-shi, Okayama, Sapporo, Shibuya-ku, Shinjuku-ku, Suita-shi
2026-06-26
Recruiting
AstraZeneca
Phase 3
508
Bunkyō City, Kashiwa, Kyoto, Nagoya, Shibuya-ku, Shinjuku-ku
2026-02-23
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca
Phase 1/2
152
Bunkyō City, Kashiwa, Kurume-shi, Kyoto, Niigata, Shinjuku-ku, Toyoake-shi
2025-11-24
Recruiting
AstraZeneca
Phase 3
400
Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kashiwa, Kawasaki-shi, Kyoto, Matsuyama
2025-10-31
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
AstraZeneca
Observational
64
Kashiwa, Kyoto, Osakasayama-shi
2025-09-17
Recruiting
AstraZeneca
Phase 2
278
Bunkyō City, Fukuyama-shi, Kobe, Kurume-shi, Kyoto, Osaka, Sakaishi, Shinjuku-ku
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Bunkyō City, Fukuoka, Kamakura-shi, Kawagoe-shi, Kawasaki-shi, Kisarazu-shi, Kumamoto, Kyoto
2025-08-06
Recruiting
AstraZeneca
Phase 1
72
Bunkyō City, Kita-gun, Kitakyushu-shi, Kyoto, Nagasaki
2025-05-01
Recruiting
AstraZeneca
Phase 3
5,250
Chūōku, Fujieda-shi, Fukuoka, Kitakyushu, Kobe, Kure-shi, Kyoto, Minoh
2024-02-21
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
255
Bunkyō City, Chiba, Chūōku, Fukuoka, Kashiwa, Kyoto, Okayama, Osaka
2023-12-29
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Nagoya, Kashiwa-shi, Kurume, Kanazawa, Yokohama, Kyoto, Sendai, Ōsaka-sayama
2023-12-20
Active, closed
AstraZeneca
Phase 3
142
Chūōku, Kanazawa, Kashiwa, Kyoto, Osaka, Sendai, Ube, Wakayama
2023-08-16
Active, closed
AstraZeneca
Phase 3
390
Chiba, Fukuoka, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata, Osaka
2022-02-21
Active, closed
AstraZeneca
Phase 3
893
Chiba, Chūōku, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kōtoku, Kyoto
2021-05-10
Active, closed
AstraZeneca
Phase 3
358
Akashi-shi, Bunkyō City, Chiba, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata
2020-12-16
Active, closed
AstraZeneca
Phase 3
805
Chūōku, Kashiwa-shi, Kōtoku, Kurume-shi, Kyoto, Matsuyama, Minatoku, Nagoya
2020-05-05
Active, closed
AstraZeneca
Phase 3
1,407
Fukuoka, Kashiwa-shi, Kobe, Kōtoku, Kurume-shi, Kyoto, Minatoku, Nagoya
2019-01-04
Active, closed
AstraZeneca
Phase 3
895
Bunkyō City, Hirakata-shi, Kanazawa, Kashihara-shi, Kawagoe-shi, Kita-gun, Kyoto, Maebashi
2018-10-31
Rows per page Showing 1–21 of 21
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kyoto

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 21 of those studies with a site in Kyoto that also match the filters currently applied.

How many clinical trials are recruiting in Kyoto?

13 of the 21 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kyoto), 21 studies
PhaseStudiesRecruitingShare
Phase 315871.4%
Observational219.5%
Phase 1/2229.5%
Phase 1114.8%
Phase 2114.8%

Most active sponsors

Lead sponsors with the most studies (Kyoto)
Lead sponsorStudiesRecruiting
AstraZeneca2113
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.